An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...
An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, gene ...
Researchers at Imperial College London are leading human trials for the innovative treatmentAn inhalable medicine with the potential to improve lung ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果